- Conditions
- Infections, Bacterial
- Interventions
- GSK1322322 (mesylate salt) Powder for Injection, GSK1322322 (freebase) tablets, GSK1322322 (mesylate salt) Powder for Oral Solution, GSK1322322 (freebase) tablets FED
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 27
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Solid Tumor
- Interventions
- YL-13027
- Drug
- Lead sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Autism, Autism Spectrum Disorder
- Interventions
- Epidiolex, placebo oral solution
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 7 Years to 14 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Weight Loss
- Interventions
- Placebo, VK2735
- Drug
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Peoria, Arizona • Lake Forest, California • Clearwater, Florida + 12 more
- Conditions
- PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
- Interventions
- SER-252 (PEOZ-apomorphine), enFuse
- Drug · Device
- Lead sponsor
- Serina Therapeutics
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 1 more
- Conditions
- Bioavailability
- Interventions
- Remimazolam
- Drug
- Lead sponsor
- Paion UK Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Sleep, THC, Marijuana, Cannabis
- Interventions
- Dronabinol
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 34 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Dupilumab, Matching Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
- Conditions
- Nonconvulsive Electrographic Seizures
- Interventions
- Brivaracetam intravenous solution, Brivaracetam oral tablets, Phenytoin intravenous solution, Phenytoin oral tablets
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Jackson, Mississippi
- Conditions
- Cytomegalovirus Infections
- Interventions
- Valganciclovir, Ganciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 30 Days
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more
- Conditions
- Solid Tumors, Hematologic Malignancies
- Interventions
- Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2043
- U.S. locations
- 65
- States / cities
- Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more
- Conditions
- Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
- Interventions
- Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Down Syndrome
- Interventions
- Donepezil HCl, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 25 more
- Conditions
- Cystic Fibrosis
- Interventions
- Linezolid
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV Prevention
- Interventions
- Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation
- Drug
- Lead sponsor
- Ian McGowan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Pittsburgh, Pennsylvania
- Conditions
- Community-acquired Bacterial Pneumonia
- Interventions
- Solithromycin, Standard of Care
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 2 Months to 17 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more
- Conditions
- Healthy Participants
- Interventions
- AZD5004
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 17
- States / cities
- Orange, California • Palo Alto, California • San Francisco, California + 14 more
- Conditions
- HIV Infections
- Interventions
- ATV, Ritonavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 91 Days to 21 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2014
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more
- Conditions
- Acute Myocardial Infarction
- Interventions
- CSL112, Placebo
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Tadalafil- Tablet or Oral suspension
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more
- Conditions
- Venous Thromboembolism
- Interventions
- dabigatran etexilate, standard of care
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 9
- States / cities
- Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
- Conditions
- Acute Myocardial Infarction, Moderate Renal Impairment
- Interventions
- CSL_112, Placebo
- Biological · Other
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more